Eva-Lotta

Non-Executive Director, Independent

[Eva-Lotta @evil_otter]

@BBCNews N

[Maxion Therapeutics @MaxionTx]

Excited to announce our new CEO, Dr Arndt Schottelius! An experienced biotech & pharma executive, Arndt will take Maxion to its next phase of development. Current CEO Dr John McCafferty will become CTO.

#CEO #antibodies #KnotBodies #ionchannels #GPCR
#drugdevelopment

[Eva-Lotta @evil_otter]

I’m thrilled to be working with John and Aneesh and the rest of the Board at Maxion Therapeutics #KnotBodies #antibodies #maxiontherapeutics

[Maxion Therapeutics @MaxionTx]

Excited to share that senior industry leader (@evil_otter) has been appointed Chair of our Board! Eva-Lotta’s corporate, BD and operational experience strengthens our team as our lead programme progresses to preclinical development.
#lifesciences #antibodies #KnotBodies

[Crescendo Biologics @HUMABODY]

Join our VP Discovery, Colette Johnston at the European Multispecific Antibody Congress 2023 (22-23 Feb) in Amsterdam, where she will be presenting “CB307: A Novel Multispecific T-Cell Costimulatory Humabody VH Therapeutic for Immuno-Oncology”

[Dogs Trust 💛🐶 @DogsTrust]

RT if you think Cole is cute enough to be on a Christmas card 😍🎄👏

@DT_Glasgow 📍

[Crescendo Biologics @HUMABODY]

Our CEO, Theodora Harold, CDO, Philip Bland-Ward, and CFO, Mike Booth, will be in San Francisco for #JPM2023. If you would like to discuss our Humabody platform and T cell enhancing pipeline, please contact us at [email protected]

[Eva-Lotta @evil_otter]

@HUMABODY Great News !

[Circio Holding ASA @circio_asa]

Targovax’s study of ONCOS-102 and pembrolizumab has been accepted for publication in Clinical Cancer Research

https://t.co/hgBz7b8aHl

[Crescendo Biologics @HUMABODY]

We are looking forward to attending ON Helix in Cambridge (7 July).

If you would like to meet our team to discuss our Humabody® VH platform or T cell enhancing immuno-oncology pipeline of CD137-targetting bispecific molecules, please contact us at [email protected]

[Crescendo Biologics @HUMABODY]

We are pleased to announce the selection and nomination of the second wholly-owned clinical candidate from our proprietary T cell enhancing CD137 franchise. CB693 is a half-life extended CD137 x MSLN Humabody bispecific.
https://t.co/e5bua2NOPd

[joe jacobson @joe_jacobson]

To say thank you for the support over the last 8 years I’m giving away 2 @wwfcofficial signed shirts from last season. Just retweet, like and follow for a chance to win one!! You have one week!! Good luck.

[Crescendo Biologics @HUMABODY]

Join our CEO, Theodora Harold at BIC 2022 (23 Jun), where she will be speaking about “The life of a scale-up company at Babraham Research Campus”
Crescendo Biologics is an immuno-oncology company with a Phase 1 lead programme, CB307

[Crescendo Biologics @HUMABODY]

We are pleased to be attending the upcoming Citi European Healthcare Conference 2022 (16 Jun) and William Blair Emerging Biotechnology Stars in Europe Conference (19 Jul).

If you would like to meet the team, please contact us via [email protected]

[Crescendo Biologics @HUMABODY]

We are looking forward to joining the medical and research community at #ASCO22 in Chicago. To meet the team to discuss our Humabody® platform and T cell enhancing pipeline, please contact us at [email protected]

[Circio Holding ASA @circio_asa]

We are excited to announce a collaboration with Oslo University Hospital to test TG mutant RAS vaccination in patients with multiple myeloma.
Dr. Fredrik Schjesvold will lead the trial. For more information, see here: https://t.co/ulzJKi9oe1

[Circio Holding ASA @circio_asa]

Join our CSO Victor Levitsky at the Cancer Progress Conference 2022
https://t.co/75zdgzMgkt
#cancer #immunotherapy #cancerresearch #immunooncology #clinicaltrials

[Circio Holding ASA @circio_asa]

We’re thrilled to announce a clinical collaboration with Agenus for upcoming ONCOS-102 phase 2 melanoma trial!
For more information, see https://t.co/CC6TzI3gXl

#cancer #immunotherapy #cancerresearch #immunooncology #clinicaltrials

[Crescendo Biologics @HUMABODY]

Join our VP Discovery, Colette Johnston, at #PEGS22 in Boston on 3 May, where she will present a talk and poster on “CB307: A Novel T Cell Costimulatory Humabody VH Therapeutic for PSMA-Positive Tumours”

[Circio Holding ASA @circio_asa]

Our CEO, Erik Digman Wiklund, will be attending and presenting at the #DKBIO 6-7th April, hosted in Boston by the Innovation Centre Denmark. The event connects Scandinavian bioscience companies with US corporates and investors. Let us know if you want to connect!

[Crescendo Biologics @HUMABODY]

Join our VP, Discovery, Colette Johnston and AD, CMC Process Development, Neil Birkett, at the Biologics UK Conference on 21-22 March, presenting “Bispecific CAR-Ts Using Crescendo VH” and “Our CB307 Humabody® journey: From Process Development To The Patient”. #BiologicsSeries22